Zacks Investment Research
07 Aug 2026, 15:46 UTC · 10w ago
Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones
Impact · against what's priced in
Moderna's Q2 results show a modest revenue beat and improved cost discipline, which lowers the cash burn rate. The positive regulatory progress on the seasonal flu vaccine creates a concrete path for revenue diversification away from COVID-19.
- MRNA+0.30
No priced-in read yet
- In context
The company beat Q2 revenue estimates ($145M vs $126.6M) and reduced its 2026 cash cost guidance by $0.2 billion, while securing a unanimous U.S. advisory committee recommendation for its flu vaccine.
Read from the article alone
